Genmab files for $500M IPO to fund multi-front cancer R&D push

Genmab has filed to raise up to $500 million (€448 million) in an IPO on the Nasdaq exchange. The huge offering will set Genmab up to take antibody-drug conjugate (ADC) tisotumab vedotin to market in cervical cancer while pushing other programs through the clinic.